Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

2.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
2.2K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Teratogenicity01:07

Teratogenicity

4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
Local Anesthetics: Clinical Application as Epidural Anesthesia01:29

Local Anesthetics: Clinical Application as Epidural Anesthesia

1.1K
Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
1.1K
Diphtheria01:28

Diphtheria

187
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
187
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

1.3K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Socioeconomic gradients in hypertension prevalence and management: a cross-sectional study.

BMC public health·2026
Same author

Postoperative Complications and Long-Term Cardiovascular Risk After Gastrectomy for Gastric Cancer.

Annals of surgical oncology·2026
Same author

Diagnostic accuracy and safety of cone-beam computed tomography-guided percutaneous transthoracic lung biopsy: an updated systematic review and meta-analysis.

Diagnostic and interventional radiology (Ankara, Turkey)·2026
Same author

Response to a Letter to the Editor "interpreting prophylactic antibiotic use in closed basilar skull fractures: Caution in claims-based evidence".

The journal of trauma and acute care surgery·2026
Same author

Perspectives on the Impact of COVID-19 among Korean Americans with Chronic Hepatitis B: A Mixed Methods Exploration.

Journal of Asian health·2026
Same author

Engineered Salmonella delivering the NMDAR antagonist conantokin G synergizes with PD-L1 blockade to enhance colorectal cancer regression.

Experimental hematology & oncology·2026

Related Experiment Video

Updated: May 5, 2026

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

15.6K

Botulinum toxin type A in pregnancy.

Michael Tan, Eunji Kim, Gideon Koren

    Canadian Family Physician Medecin De Famille Canadien
    |November 16, 2013
    PubMed
    Summary

    Botulinum toxin type A (BTX-A) injections for cosmetic purposes are generally considered safe during pregnancy. Studies show BTX-A does not cross the placenta, posing no increased risk to fetal development.

    Area of Science:

    • Medical Aesthetics
    • Toxicology
    • Obstetrics

    Background:

    • Botulinum toxin type A (BTX-A) is widely used for cosmetic facial lines.
    • Patient safety during pregnancy is paramount, especially with aesthetic treatments.
    • Concerns exist regarding the systemic effects of BTX-A during gestation.

    Purpose of the Study:

    • To evaluate the safety of botulinum toxin type A (BTX-A) exposure during pregnancy.
    • To determine the risk of fetal harm following maternal BTX-A treatment for cosmetic purposes.

    Main Methods:

    • Literature review of reported pregnancies with BTX-A exposure.
    • Analysis of cases involving botulism poisoning during pregnancy.
    • Assessment of BTX-A's pharmacokinetic properties, including placental transfer.

    More Related Videos

    A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
    10:30

    A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

    Published on: December 27, 2013

    5.0K
    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
    14:10

    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

    Published on: November 14, 2014

    7.9K

    Related Experiment Videos

    Last Updated: May 5, 2026

    Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
    12:25

    Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

    Published on: March 3, 2014

    15.6K
    A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
    10:30

    A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

    Published on: December 27, 2013

    5.0K
    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
    14:10

    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

    Published on: November 14, 2014

    7.9K

    Main Results:

    • Botulinum toxin type A is not detected in systemic circulation after standard injections.
    • BTX-A's high molecular weight prevents placental crossing.
    • Review of 38 pregnancies showed no increased risk of adverse fetal outcomes.

    Conclusions:

    • Maternal BTX-A treatment for facial lines is not associated with increased fetal risk.
    • The localized nature and molecular properties of BTX-A limit systemic exposure and placental transfer.
    • Existing literature suggests safety for pregnant individuals undergoing cosmetic BTX-A procedures.